Center for Genetic Engineering

The Center for Genetic Engineering and Biotechnology (CIGB) is a leading Cuban biotechnology institution focused on the research, development, production, and marketing of high-tech biological products. Established in 1986, it operates as a vertically integrated enterprise covering the entire value chain from basic research to industrial-scale manufacturing and global commercialization. CIGB is best known for developing the Abdala COVID-19 vaccine and Heberprot-P, a unique therapy for diabetic foot ulcers that significantly reduces amputation rates. The center's portfolio includes a wide range of recombinant proteins, vaccines, and monoclonal antibodies targeting infectious diseases, oncology, and cardiovascular conditions.